Citius Pharmaceuticals (CTXR) Financials

Citius Pharmaceuticals (NASDAQ: CTXR) continues to look like a high-risk, cash-burning biotech with meaningful balance sheet changes over the past year. The latest quarter shows a sharp rebound in cash, but that improvement was driven primarily by financing and large noncash balance sheet shifts rather than operating profitability. Revenue also remains lumpy and the company is still posting substantial losses.

• Cash and equivalents improved sharply quarter over quarter. Cash rose to $4.6 million in Q2 2026 from $0.8 million in Q1 2026, indicating the company has recently bolstered liquidity.
• Current assets exceeded current liabilities in Q2 2026. Total current assets were $31.7 million versus $55.0 million in current liabilities, but the company still has a sizable current asset base, helped by inventories and receivables.
• Revenue is still being generated. Q2 2026 revenue was $1.7 million, and Q1 2026 revenue was $3.9 million, showing the business is not pre-revenue.
• Gross margin remained solid in Q2 2026. Gross profit of $1.34 million on $1.67 million in revenue suggests the company can produce product-level profitability before overhead.
• Cash declined much less in the latest quarter than in earlier periods. Operating cash burn in Q2 2026 was only $1.3 million, an improvement versus prior quarters that saw much heavier operating outflows.
• Interest and investment income helped offset losses. In Q2 2026, other income was $3.85 million, which reduced pre-tax losses, but it did not change the overall negative earnings picture.
• Noncontrolling interests remain material. CTXR’s reported results are influenced by noncontrolling interest, which can make comparisons less straightforward for common shareholders.
• Operating losses remain very large. Q2 2026 operating loss was $32.2 million, far larger than revenue, showing the core business is still deeply unprofitable.
• Net losses widened significantly in Q2 2026. The company reported a net loss of $28.1 million, or $0.95 per share, compared with a $9.4 million loss in Q1 2026.
• Operating cash flow remains negative. Even after noncash adjustments, CTXR used $1.3 million in operating cash in Q2 2026, and its multi-year history shows persistent cash burn.

Looking at the trend across the last four years, the company’s financial profile has been volatile and heavily dependent on capital raises. Cash balances have swung widely from quarter to quarter, common stock has grown substantially, and financing inflows frequently support operations. That pattern suggests dilution risk remains a key issue for retail investors.

The balance sheet also reflects a company built more around intangible assets than hard assets. At Q2 2026, total assets were $132.5 million, including $90.5 million of intangible assets and $9.3 million of goodwill, while PP&E was essentially zero. This points to a business value structure tied to acquired assets and intellectual property rather than plant and equipment.

Bottom line: CTXR has recently improved liquidity, but the business still faces major challenges: large losses, negative operating cash flow, and a history of relying on equity issuance to stay funded. For investors, the stock remains a speculative biotech name where financing progress matters almost as much as operating performance.